PubMed Commons to Stop Accepting Comments

The venue for post-publication peer review was not getting enough participation.

Written byKerry Grens
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA, CANJIE6As of February 15, PubMed Commons, a site where verified users can discuss one another’s papers, will stop taking reader comments. The National Center for Biotechnology Information (NCBI) announced last week (February 1) that only 6,000 papers out of the 28 million in PubMed’s database had received any reviews, prompting the agency to end its efforts into the program.

“While many worthwhile comments were made through the service during its 4 years of operation, [the National Institutes of Health] has decided that the low level of participation does not warrant continued investment in the project, particularly given the availability of other commenting venues,” NCBI says in the statement.

PubPeer, for instance, has had much more success. Retraction Watch reports that the site hosts comments on nearly 70,000 scientific papers, and the team there credits that in part to greater a permissiveness on its site than PubMed Commons offered.

“Compared to PubPeer, PubMed Commons forbade anonymity,” PubPeer leaders say in a statement to Retraction Watch. “We have always felt that many users, particularly those with the most significant criticisms, prefer to comment anonymously in order ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies